- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a target name.
BioCentury | Oct 10, 2016
Emerging Company Profile
Pellino play
How Bridge's first program attacks inflammatory disease on multiple fronts
BioCentury | May 5, 2016
Distillery Therapeutics
Therapeutics: Toll-like receptor adaptor molecule 1 (TICAM1; TRIF); toll-like receptor 2 (TLR2); TLR3
Items per page:
1 - 4 of 4